OrbitonOpen research workspace →
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

TSX:CRDLLive AI agent

Cardiol Therapeutics Inc.

Investor website: https://www.cardiolrx.com/

About

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

Verified company data

Cash position
$83.9M
Shares outstanding
116.18m
Fully diluted shares
120.66m
Projects
["CardiolRx™ (cannabidiol) oral solution is in clinical development for use in the treatment of heart disease. CardiolRx™ attenuates multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, which is known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. CardiolRx™ is pharmaceutically manufactured under cGMP to meet the highest standards for product purity, consistency, and stability. A Phase I safety and pharmacokinetic study of single and multiple ascending doses of CardiolRx™ was completed and demonstrated that CardiolRx™ was safe and generally well tolerated at all dose levels, with no serious adverse events reported. The results supported the Company’s two Investigational New Drug Application authorizations from the United States Food and Drug Administration to conduct two Phase II studies in rare heart diseases: recurrent pericarditis and acute myocarditis. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. CardiolRx™ is also eligible for FDA ODD in acute myocarditis and European Medicine Agency orphan medicine designations for recurrent pericarditis and acute myocarditis.","CRD-38 is a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. We are undertaking IND-enabling activities to support clinical evaluation of CRD-38 as a therapeutic strategy in heart failure care. We are currently developing CRD-38 that is intended to improve the pharmacokinetic profile compared to existing formulations. Subcutaneous administration has the potential to allow for a lower dose of drug to be delivered with less frequent administration, while achieving the same or greater therapeutic effect. Our research collaborators have shown that cannabidiol, when administered subcutaneously, is effective in a pre-clinical model of heart failure. The subcutaneous approach is practical and widely used in human medicine although the formulation requires specific characteristics. We have successfully developed a formulation that meets these required characteristics. Currently, this formulation is undergoing pharmacokinetic testing."]
Leadership
David Elsley, MBA (President and Chief Executive Officer), Andrew Hamer, MBChB (Chief Medical Officer and Head of Research & Development), Chris Waddick, MBA, CPA, CMA (Chief Financial Officer), Bernard Lim, MIET, CEng (UK) (Chief Operating Officer), Andrea B. Parker, MSc, PhD (Vice President of Clinical Operations and Study Design), John A. Geddes, MBA (Vice President, Corporate Development), Anne Tomalin, BA, BSc, RAC (Senior Director of Regulatory and Quality), Dan Crandall, CPA, CA (Vice President of Finance), Guillermo Torre-Amione, MD, PhD (Chairman), Jennifer M. Chao, BA (Director), Teri Loxam, MBA (Director), Peter Pekos, BSc, MSc (Director), Colin G. Stott, BSc (Hons) (Director), Tim Garnett, MD (Director), Paul M. Ridker, MD, MPH (Director), Bruce McManus, PhD, MD (Director), Joseph A. Hill, MD, PhD (Director), Allan Klein, MD, CM (Pericarditis Advisor Study Chair), Paul Cremer, MD (Pericarditis Advisor), Allen Luis, MBBS, PhD (Pericarditis Advisor), Dor Lotan, MD (Pericarditis Advisor), Antonio Abbate, MD, PhD (Pericarditis Advisor), Stefano Toldo, PhD (Pericarditis Advisor), Stephen Nicholls, MBBS, PhD (Pericarditis Advisor), Tom Wang, MBChB, MD (Pericarditis Advisor), Mohamed Al-Kazaz, MD (Pericarditis Advisor), Dennis M. McNamara, MD (ARCHER Steering Committee Chair), Leslie T. Cooper, Jr., MD (ARCHER Steering Committee Co-Chair), Arvind Bhimaraj, MD (ARCHER Steering Committee), Wai Hong Wilson Tang, MD (ARCHER Steering Committee), Peter Liu, MD (ARCHER Steering Committee), Carsten Tschöpe, MD (ARCHER Steering Committee), Matthias Friedrich, MD (ARCHER Steering Committee), Edimar Bocchi, MD (ARCHER Steering Committee), Yaron Arbel, MD (ARCHER Steering Committee), Mathieu Kerneis, MD, PhD (ARCHER Steering Committee)

Verified data last updated:

Recent filings

Investor FAQ

About Cardiol Therapeutics Inc. (TSX:CRDL)